First Participant Screened in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe

On July 18, 2022, the first UK participant in our open-label Phase 2 study of MDMA-assisted therapy for PTSD was screened by the research team at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London – South London and Maudsley NHS Trust (KCL-SLaM). The site principal investigator is Dr. James Rucker.